Skip to main content
. 2021 Jan 28;17(1):e1007900. doi: 10.1371/journal.pcbi.1007900

Fig 3. Cell lines data: Mutations and sensitivities to BRAF inhibition.

Fig 3

(A) Distribution of the assigned mutations in the four most frequently mutated genes in the colorectal/melanoma cohort of cell lines [37]. (B) Differential sensitivities to BRAF inhibition by the drug PLX-4720 (upper panel) or by CRISPR inhibition (lower panel), depending on BRAF mutational status and cancer type. Numbers of cell lines in each category are indicated. Note that high sensitivities correspond to low AUC and high scaled Bayesian factors.